CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Fundação Antonio Prudente (FAP). A C Camargo Cancer Center (Institutional affiliation from the last research proposal) Birthplace: Brazil
Did his undergraduation in Biomedicine and his Master's in Biology of Infectious Agents at the Federal University of Pará. In 2014, he defended his PhD thesis in the Post-graduation Program of Basic and Applied Immunology at the Medical School of Ribeirão Preto from the University of São Paulo (USP). From March 2014 to June 2018, he did his post-doctoral training at the Princess Margaret Cancer Research Centre, in Toronto, Canada, which is is one of the top 5 cancer research centres in the world. He currently is a Scientific Researcher of the A.C.Camargo Cancer Center, in São Paulo, where he leads the Translational Imuno-oncology Group. He is also the coordinator of the Flow Cytometry Facility from the Translational Imuno-oncology Group and supervisor of the Oncology Post-Graduation Program at the Antonio Prudente Foundation/A.C.Camargo Cancer Center, where he lectures post-graduation courses of Immune-Oncology and Epigenetic Regulation of the Immune Response. He currently is the coordinator of the Committee on Animal Research and Ethics (REB) and member of the Institutional Biosafety and Scientific Initiation Committees from the Antonio Prudente Foundation. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The immune system in cancer patients is normally compromised, as the tumor microenvironment has a drastic effect on immune cell populations, given its ability to promote alternatively activated immune cells. Such immune cells are unable to destroy cancer (initiating) cells, as they are either exhausted or polarized towards an anti-inflammatory profile. Immune checkpoint inhibitors have em…
Chimeric Antigen Receptor T-cell therapy (CAR-T) stands as a significant breakthrough in the evolving field of immunotherapy. However, due to the lack of well-defined molecular targets in solid tumors, its efficacy has been confined to the treatment of hematological malignancies. The diverse repertoire of B cell receptors (BCR) suggests the presence of a specific B cell subpopulation with…
Endogenous Retroviral Elements (EREs) are genomic DNA fragments that may retain the capability of replication and reinsertion into the host genome, affecting its structure and integrity. Such are usually deregulated in many human cancers and may trigger the cellular immunogenicity through the activation of innate and adoptive immunity, thus representing promising candidates as immunothera…
The immune system in cancer patients is normally compromised, as the tumor microenvironment has a drastic effect on immune cell populations, given its ability to promote alternatively activated immune cells. Such immune cells are unable to destroy cancer (initiating) cells, as they are either exhausted or polarized towards an anti-inflammatory profile. Immune checkpoint inhibitors have em…
Pancreatic Ductal Adenocarcinoma (PDA) is a lethal disease with a median survival of <11 months. Surgical resection is the only potentially curative therapeutic option, and emerging strategies to improve PDA prognosis include the molecular stratification of tumors into biologically homogenous subgroups, and the development of immunotherapies. Over the past years, immune checkpoint inhibit…
(Only some records are available in English at this moment)
| 1 / 1 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 4 / 4 | Completed scholarships in Brazil |
| 6 / 6 | All research grants and scholarships |
| Associated processes | |